Department of Chemical Engineering, Institute for Applied Life Sciences, University of Massachusetts, Amherst, MA, 01003, USA.
Department of Medicine, UMass Chan Medical School, Worcester, MA, 01605, USA.
Nat Commun. 2023 Dec 7;14(1):8092. doi: 10.1038/s41467-023-44000-9.
Osteoclasts are the primary target for osteoporosis drug development. Recent animal studies revealed the crucial roles of osteoblasts in regulating osteoclastogenesis and the longer lifespans of osteoclasts than previously thought with fission and recycling. However, existing culture platforms are limited to replicating these newly identified cellular processes. We report a demineralized bone paper (DBP)-based osteoblast culture and osteoclast assay platform that replicates osteoclast fusion, fission, resorption, and apoptosis with high fidelity and analytical power. An osteoid-inspired DBP supports rapid and structural mineral deposition by osteoblasts. Coculture osteoblasts and bone marrow monocytes under biochemical stimulation recapitulate osteoclast differentiation and function. The DBP-based bone model allows longitudinal quantitative fluorescent monitoring of osteoclast responses to bisphosphonate drug, substantiating significantly reducing their number and lifespan. Finally, we demonstrate the feasibility of humanizing the bone model. The DBP-based osteo assay platforms are expected to advance bone remodeling-targeting drug development with improved prediction of clinical outcomes.
破骨细胞是骨质疏松症药物开发的主要靶点。最近的动物研究揭示了成骨细胞在调节破骨细胞生成中的关键作用,以及破骨细胞比以前认为的具有更长的分裂和循环寿命。然而,现有的培养平台仅限于复制这些新发现的细胞过程。我们报告了一种基于脱矿骨纸(DBP)的成骨细胞培养和破骨细胞检测平台,该平台具有高度保真度和分析能力,可以复制破骨细胞融合、分裂、吸收和凋亡。类骨质启发的 DBP 支持成骨细胞快速和结构的矿化沉积。在生化刺激下共培养成骨细胞和骨髓单核细胞可再现破骨细胞的分化和功能。基于 DBP 的骨模型允许对破骨细胞对双膦酸盐药物的反应进行纵向定量荧光监测,证实其数量和寿命显著减少。最后,我们证明了使骨模型人源化的可行性。基于 DBP 的成骨细胞检测平台有望推进针对骨重塑的药物开发,从而改善对临床结果的预测。